KPC Pharmaceuticals, Inc.

Shanghai Stock Exchange 600422.SS

KPC Pharmaceuticals, Inc. Revenue Per Share for the year ending December 31, 2023: USD 1.44

KPC Pharmaceuticals, Inc. Revenue Per Share is USD 1.44 for the year ending December 31, 2023, a -9.88% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • KPC Pharmaceuticals, Inc. Revenue Per Share for the year ending December 31, 2022 was USD 1.60, a -6.75% change year over year.
  • KPC Pharmaceuticals, Inc. Revenue Per Share for the year ending December 31, 2021 was USD 1.71, a 10.00% change year over year.
  • KPC Pharmaceuticals, Inc. Revenue Per Share for the year ending December 31, 2020 was USD 1.56, a 1.69% change year over year.
  • KPC Pharmaceuticals, Inc. Revenue Per Share for the year ending December 31, 2019 was USD 1.53, a 13.98% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
Shanghai Stock Exchange: 600422.SS

KPC Pharmaceuticals, Inc.

CEO Mr. Sun Zhi Qiang
IPO Date Dec. 6, 2000
Location China
Headquarters No.166 Keyi Road
Employees 5,051
Sector Health Care
Industries
Description

KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.

Similar companies

600479.SS

ZhuZhou QianJin Pharmaceutical Co.,Ltd

USD 1.39

2.42%

600420.SS

Shanghai Shyndec Pharmaceutical Co., Ltd.

USD 1.57

3.15%

600535.SS

Tasly Pharmaceutical Group Co., Ltd

USD 1.91

2.05%

600436.SS

Zhangzhou Pientzehuang Pharmaceutical., Ltd

USD 28.52

2.04%

600380.SS

Joincare Pharmaceutical Group Industry Co.,Ltd.

USD 1.47

0.94%

StockViz Staff

January 15, 2025

Any question? Send us an email